Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.…
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
Tiziana Life Sciences (NASDAQ: TLSA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 0.6206 USD on 20 November 2026, down 64.3% over 52 weeks. Its 52-week range is 0.5503 USD to 1.900 USD: the price is 67.3% below the high and 12.8% above the low.
Its market capitalisation is 79.45M USD.
Tiziana Life Sciences reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.25M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.